HRP20000712A2 - PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION - Google Patents
PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION Download PDFInfo
- Publication number
- HRP20000712A2 HRP20000712A2 HR20000712A HRP20000712A HRP20000712A2 HR P20000712 A2 HRP20000712 A2 HR P20000712A2 HR 20000712 A HR20000712 A HR 20000712A HR P20000712 A HRP20000712 A HR P20000712A HR P20000712 A2 HRP20000712 A2 HR P20000712A2
- Authority
- HR
- Croatia
- Prior art keywords
- pyridin
- mmol
- title compound
- preparation
- compound
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 6
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title claims description 5
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title claims 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 title 1
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
- 231100000872 sexual dysfunction Toxicity 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 618
- 239000000203 mixture Substances 0.000 claims description 248
- 238000000034 method Methods 0.000 claims description 127
- -1 2-(morpholin-4-yl)ethyl Chemical group 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 45
- 239000012453 solvate Substances 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 17
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 15
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 14
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 14
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000009109 curative therapy Methods 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 206010021639 Incontinence Diseases 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 7
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 201000009961 allergic asthma Diseases 0.000 claims description 7
- 201000010105 allergic rhinitis Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 206010006451 bronchitis Diseases 0.000 claims description 7
- 208000023819 chronic asthma Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010016256 fatigue Diseases 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 201000001881 impotence Diseases 0.000 claims description 7
- 230000002028 premature Effects 0.000 claims description 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 6
- 230000025033 vasoconstriction Effects 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 230000008991 intestinal motility Effects 0.000 claims description 5
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- UVDGHQGDUKNVRA-UHFFFAOYSA-N 3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCCOC)=O)C2=C(CC)N1CC1=CC=CC=N1 UVDGHQGDUKNVRA-UHFFFAOYSA-N 0.000 claims description 3
- MPNWKIDRINJSMK-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CC[N+]([O-])(CC)CC3)OCCOC)=O)C2=C(CC)N1CC1=CC=CC=N1 MPNWKIDRINJSMK-UHFFFAOYSA-N 0.000 claims description 3
- QDPNAMRLQRQPMR-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=C1 QDPNAMRLQRQPMR-UHFFFAOYSA-N 0.000 claims description 3
- WKISNFXGTYNPOO-OAHLLOKOSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2r)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@H](C)COC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 WKISNFXGTYNPOO-OAHLLOKOSA-N 0.000 claims description 3
- ZDRAMJRYRRRBJN-UHFFFAOYSA-N 5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCCOC)=O)C2=C(CCC)N1CC1=CC=CC=N1 ZDRAMJRYRRRBJN-UHFFFAOYSA-N 0.000 claims description 3
- INFYRZAJYPRAJM-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCCOC)=O)C2=C(CCC)N1CC1=CC=CC=N1 INFYRZAJYPRAJM-UHFFFAOYSA-N 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 2
- XPLAHBQULJNNLX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ol Chemical compound C1=CC=C2OC(O)COC2=C1 XPLAHBQULJNNLX-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- QNQGEMHZYKZNBS-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(1-pyridin-2-ylethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2C(C)C1=CC=CC=N1 QNQGEMHZYKZNBS-UHFFFAOYSA-N 0.000 claims description 2
- UACYIMXLEVRBDV-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-[(6-methoxypyridin-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CC(OC)=N1 UACYIMXLEVRBDV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 206010047139 Vasoconstriction Diseases 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 claims 2
- 101150098694 PDE5A gene Proteins 0.000 claims 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 801
- 238000002360 preparation method Methods 0.000 description 467
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 464
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 452
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 349
- 239000007787 solid Substances 0.000 description 206
- 239000000243 solution Substances 0.000 description 201
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 199
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 154
- 235000019439 ethyl acetate Nutrition 0.000 description 118
- 238000010898 silica gel chromatography Methods 0.000 description 99
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 96
- 239000011541 reaction mixture Substances 0.000 description 93
- 238000010828 elution Methods 0.000 description 89
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 70
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 70
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- 239000003480 eluent Substances 0.000 description 68
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 239000006260 foam Substances 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- 239000003921 oil Substances 0.000 description 56
- 235000019198 oils Nutrition 0.000 description 56
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 53
- 239000012267 brine Substances 0.000 description 51
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 51
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 49
- 239000000725 suspension Substances 0.000 description 45
- 239000012071 phase Substances 0.000 description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
- 238000010992 reflux Methods 0.000 description 43
- 239000000284 extract Substances 0.000 description 41
- 239000000741 silica gel Substances 0.000 description 41
- 229910002027 silica gel Inorganic materials 0.000 description 41
- 238000004587 chromatography analysis Methods 0.000 description 40
- 239000008346 aqueous phase Substances 0.000 description 36
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 35
- 239000000706 filtrate Substances 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 239000007832 Na2SO4 Substances 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 229910052938 sodium sulfate Inorganic materials 0.000 description 27
- 235000011152 sodium sulphate Nutrition 0.000 description 27
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 26
- 235000017557 sodium bicarbonate Nutrition 0.000 description 26
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 21
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 239000012258 stirred mixture Substances 0.000 description 18
- 239000011734 sodium Substances 0.000 description 17
- FRDAATYAJDYRNW-UHFFFAOYSA-N 3-methyl-3-pentanol Chemical compound CCC(C)(O)CC FRDAATYAJDYRNW-UHFFFAOYSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 14
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 14
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 14
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 14
- 229910000024 caesium carbonate Inorganic materials 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 229910021529 ammonia Inorganic materials 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 229910000029 sodium carbonate Inorganic materials 0.000 description 13
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 12
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 12
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 12
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 150000001412 amines Chemical group 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 12
- 229940001593 sodium carbonate Drugs 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000001665 trituration Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000007868 Raney catalyst Substances 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 150000004703 alkoxides Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 5
- 210000005226 corpus cavernosum Anatomy 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 3
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 description 3
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 3
- 229940093475 2-ethoxyethanol Drugs 0.000 description 3
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010002153 Anal fissure Diseases 0.000 description 3
- 208000016583 Anus disease Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000009531 Fissure in Ano Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010040893 Skin necrosis Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 206010001053 acute respiratory failure Diseases 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000008706 hypoxic vasoconstriction Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- WAJNANMQOPCIPO-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-7-one Chemical class O=C1N=CN=C2C=NN=C12 WAJNANMQOPCIPO-UHFFFAOYSA-N 0.000 description 3
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 3
- 201000004193 respiratory failure Diseases 0.000 description 3
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 2
- RLDCWDJZZCOUAW-UHFFFAOYSA-N 2,3-diethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methoxypropan-2-yloxy)pyridin-3-yl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OC(C)COC)C(C=2NC(=O)C3=NN(CC)C(CC)=C3N=2)=C1 RLDCWDJZZCOUAW-UHFFFAOYSA-N 0.000 description 2
- DCJIGTZMAAKMMS-UHFFFAOYSA-N 2-(1-bromoethyl)pyridine;hydrochloride Chemical compound Cl.CC(Br)C1=CC=CC=N1 DCJIGTZMAAKMMS-UHFFFAOYSA-N 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- JDIPKQBKSBWIKU-UHFFFAOYSA-N 2-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1CCl JDIPKQBKSBWIKU-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OXYHJDREXPHWMX-UHFFFAOYSA-N 3-ethyl-5-[2-(1-methoxypropan-2-yloxy)-5-(4-propylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CCC)CCN1S(=O)(=O)C1=CN=C(OC(C)COC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 OXYHJDREXPHWMX-UHFFFAOYSA-N 0.000 description 2
- AHPWULFANUCOGZ-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methoxybutan-2-yloxy)pyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)C(OC(COC)CC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 AHPWULFANUCOGZ-UHFFFAOYSA-N 0.000 description 2
- FCMDGPPBCUEITO-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-pyridin-2-ylethoxy)pyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=CN=C1OC(C)C1=CC=CC=N1 FCMDGPPBCUEITO-UHFFFAOYSA-N 0.000 description 2
- ATTDRKMNBSATKL-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-(1-pyridin-2-ylethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(C(CC)=C3N=2)C(C)C=2N=CC=CC=2)=C1 ATTDRKMNBSATKL-UHFFFAOYSA-N 0.000 description 2
- WWLFLMHZUDWQNL-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxypropoxy)pyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCC(C)OC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 WWLFLMHZUDWQNL-UHFFFAOYSA-N 0.000 description 2
- BNNWXOBXTNEJSQ-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(4-methoxybutan-2-yloxy)pyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OC(C)CCOC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 BNNWXOBXTNEJSQ-UHFFFAOYSA-N 0.000 description 2
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- MNMZAWIJLLZJIR-UHFFFAOYSA-N 5-[2-(1-ethoxypropan-2-yloxy)-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)C(OC(C)COCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 MNMZAWIJLLZJIR-UHFFFAOYSA-N 0.000 description 2
- XIPXDZHCXFCAGE-UHFFFAOYSA-N 5-[2-butan-2-yloxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-2,3-diethyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(CC)C(CC)=C3N=2)C(OC(C)CC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 XIPXDZHCXFCAGE-UHFFFAOYSA-N 0.000 description 2
- DLHYGEALTMKWLD-UHFFFAOYSA-N 5-[2-butoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CC=N1 DLHYGEALTMKWLD-UHFFFAOYSA-N 0.000 description 2
- MLOCJQVCWYTNRD-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methoxypropan-2-yloxy)pyridin-3-yl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=NC=1)OC(C)COC)=CC=1S(=O)(=O)N1CCN(CC)CC1 MLOCJQVCWYTNRD-UHFFFAOYSA-N 0.000 description 2
- MHIRLHQQTALINL-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methoxypropan-2-yloxy)pyridin-3-yl]-2-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC=1N(C)N=C(C(N2)=O)C=1N=C2C(C(=NC=1)OC(C)COC)=CC=1S(=O)(=O)N1CCN(CC)CC1 MHIRLHQQTALINL-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 238000000023 Kugelrohr distillation Methods 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 2
- XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- BTANRVKWQNVYAZ-SCSAIBSYSA-N (2R)-butan-2-ol Chemical compound CC[C@@H](C)O BTANRVKWQNVYAZ-SCSAIBSYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-SCSAIBSYSA-N (2r)-1-methoxypropan-2-ol Chemical compound COC[C@@H](C)O ARXJGSRGQADJSQ-SCSAIBSYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-BYPYZUCNSA-N (2s)-1-methoxypropan-2-ol Chemical compound COC[C@H](C)O ARXJGSRGQADJSQ-BYPYZUCNSA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- OWBTYPJTUOEWEK-QWWZWVQMSA-N (R,R)-butane-2,3-diol Chemical compound C[C@@H](O)[C@@H](C)O OWBTYPJTUOEWEK-QWWZWVQMSA-N 0.000 description 1
- VLLHEPHWWIDUSS-ONEGZZNKSA-N (e)-4-methoxybut-3-en-2-one Chemical compound CO\C=C\C(C)=O VLLHEPHWWIDUSS-ONEGZZNKSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- QHVYJSBQXIIROJ-UHFFFAOYSA-N 1,2,6-trimethylpiperazine Chemical compound CC1CNCC(C)N1C QHVYJSBQXIIROJ-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ZESKRVSPQJVIMH-UHFFFAOYSA-N 1,3-dimethoxypropan-2-ol Chemical compound COCC(O)COC ZESKRVSPQJVIMH-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- BIFRCBVUTLXSMT-UHFFFAOYSA-N 1,4-dihydropyrazolo[4,3-d]pyrimidin-7-one;6-ethoxy-5-(5-ethyl-1-methylpyrazol-3-yl)pyridin-3-amine Chemical compound O=C1NC=NC2=CNN=C12.CCOC1=NC=C(N)C=C1C1=NN(C)C(CC)=C1 BIFRCBVUTLXSMT-UHFFFAOYSA-N 0.000 description 1
- VKURWFDLMTXSQC-UHFFFAOYSA-N 1,4-dihydropyrazolo[4,3-d]pyrimidin-7-one;6-ethoxy-5-(5-ethyl-1-methylpyrazol-3-yl)pyridine-3-sulfonyl chloride Chemical compound O=C1NC=NC2=CNN=C12.CCOC1=NC=C(S(Cl)(=O)=O)C=C1C1=NN(C)C(CC)=C1 VKURWFDLMTXSQC-UHFFFAOYSA-N 0.000 description 1
- RGDYLIHZSHMFHX-UHFFFAOYSA-N 1,5-diethyl-4-nitropyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC RGDYLIHZSHMFHX-UHFFFAOYSA-N 0.000 description 1
- XWPYRBXBZULFKE-UHFFFAOYSA-N 1-(5-bromo-6-chloropyridin-3-yl)sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(Cl)C(Br)=C1 XWPYRBXBZULFKE-UHFFFAOYSA-N 0.000 description 1
- DMXGFDSGVSISBY-UHFFFAOYSA-N 1-(5-bromo-6-chloropyridin-3-yl)sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CN=C(Cl)C(Br)=C1 DMXGFDSGVSISBY-UHFFFAOYSA-N 0.000 description 1
- RDXXMEQXCWOIFC-UHFFFAOYSA-N 1-(5-bromo-6-ethoxypyridin-3-yl)sulfonyl-4-methylpiperazine Chemical compound C1=C(Br)C(OCC)=NC=C1S(=O)(=O)N1CCN(C)CC1 RDXXMEQXCWOIFC-UHFFFAOYSA-N 0.000 description 1
- BTYNLIMMFZPEPA-UHFFFAOYSA-N 1-[(1-methylimidazol-2-yl)methyl]-4-nitro-5-propylpyrazole-3-carboxamide Chemical compound CCCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=NC=CN1C BTYNLIMMFZPEPA-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- BERYZYRVXLZGEU-UHFFFAOYSA-N 1-[5-bromo-6-(1,3-dimethoxypropan-2-yloxy)pyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OC(COC)COC)C(Br)=C1 BERYZYRVXLZGEU-UHFFFAOYSA-N 0.000 description 1
- ZTZWDJKVSCCIAX-UHFFFAOYSA-N 1-[5-bromo-6-(2-ethoxyethoxy)pyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1=C(Br)C(OCCOCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 ZTZWDJKVSCCIAX-UHFFFAOYSA-N 0.000 description 1
- PZQGATOUBKJZLB-UHFFFAOYSA-N 1-[5-bromo-6-(2-methoxyethoxy)pyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(Br)=C1 PZQGATOUBKJZLB-UHFFFAOYSA-N 0.000 description 1
- FYUUFFRKDDTHIL-UHFFFAOYSA-N 1-[5-bromo-6-(2-phenylmethoxyethoxy)pyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1Br)=CN=C1OCCOCC1=CC=CC=C1 FYUUFFRKDDTHIL-UHFFFAOYSA-N 0.000 description 1
- KSSIPUKLQMKYIH-UHFFFAOYSA-N 1-[5-bromo-6-(3-methoxypropoxy)pyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCCOC)C(Br)=C1 KSSIPUKLQMKYIH-UHFFFAOYSA-N 0.000 description 1
- JPJDHKLPALIWOR-UHFFFAOYSA-N 1-[5-bromo-6-(oxan-4-yloxy)pyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1Br)=CN=C1OC1CCOCC1 JPJDHKLPALIWOR-UHFFFAOYSA-N 0.000 description 1
- VIABMCZEFNBTHR-GFCCVEGCSA-N 1-[5-bromo-6-[(3r)-oxolan-3-yl]oxypyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1Br)=CN=C1O[C@H]1COCC1 VIABMCZEFNBTHR-GFCCVEGCSA-N 0.000 description 1
- VIABMCZEFNBTHR-LBPRGKRZSA-N 1-[5-bromo-6-[(3s)-oxolan-3-yl]oxypyridin-3-yl]sulfonyl-4-ethylpiperazine Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1Br)=CN=C1O[C@@H]1COCC1 VIABMCZEFNBTHR-LBPRGKRZSA-N 0.000 description 1
- VKPLCPDQLVDFSK-UHFFFAOYSA-N 1-benzyl-5-ethyl-4-nitropyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CC=C1 VKPLCPDQLVDFSK-UHFFFAOYSA-N 0.000 description 1
- BFPMCZWKUSUMKE-UHFFFAOYSA-N 1-cyclopropyl-n-methylmethanamine Chemical compound CNCC1CC1 BFPMCZWKUSUMKE-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- CSZZMFWKAQEMPB-UHFFFAOYSA-N 1-methoxybutan-2-ol Chemical compound CCC(O)COC CSZZMFWKAQEMPB-UHFFFAOYSA-N 0.000 description 1
- NCCQVNCBOLIFEF-UHFFFAOYSA-N 1-methyl-4-nitro-5-propylpyrazole-3-carboxamide Chemical compound CCCC1=C([N+]([O-])=O)C(C(N)=O)=NN1C NCCQVNCBOLIFEF-UHFFFAOYSA-N 0.000 description 1
- QBLDBZSMOABVNB-UHFFFAOYSA-N 1-methyl-4-nitro-5-propylpyrazole-3-carboxylic acid Chemical compound CCCC1=C([N+]([O-])=O)C(C(O)=O)=NN1C QBLDBZSMOABVNB-UHFFFAOYSA-N 0.000 description 1
- ORGXAHHHNKMEBW-UHFFFAOYSA-N 1-methyl-5-propylpyrazole-3-carboxylic acid Chemical compound CCCC1=CC(C(O)=O)=NN1C ORGXAHHHNKMEBW-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- QLEIDMAURCRVCX-UHFFFAOYSA-N 1-propylpiperazine Chemical compound CCCN1CCNCC1 QLEIDMAURCRVCX-UHFFFAOYSA-N 0.000 description 1
- YTPQLWVHCBATKO-UHFFFAOYSA-N 1-propylpiperazine;dihydrobromide Chemical compound Br.Br.CCCN1CCNCC1 YTPQLWVHCBATKO-UHFFFAOYSA-N 0.000 description 1
- PPHIIIRFJKDTLG-UHFFFAOYSA-N 1-pyridin-2-ylethanol Chemical compound CC(O)C1=CC=CC=N1 PPHIIIRFJKDTLG-UHFFFAOYSA-N 0.000 description 1
- OUZVHPZKCZEEIJ-UHFFFAOYSA-N 2,3-diethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC)C(CC)=C3N=2)=C1 OUZVHPZKCZEEIJ-UHFFFAOYSA-N 0.000 description 1
- PZLFVXBSHPYQAW-UHFFFAOYSA-N 2,3-diethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(3-hydroxypropoxy)pyridin-3-yl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCCO)C(C=2NC(=O)C3=NN(CC)C(CC)=C3N=2)=C1 PZLFVXBSHPYQAW-UHFFFAOYSA-N 0.000 description 1
- XRTKQKREWTYYKL-UHFFFAOYSA-N 2-(2-methoxyethoxy)-5-nitropyridine-3-carboxylic acid Chemical compound COCCOC1=NC=C([N+]([O-])=O)C=C1C(O)=O XRTKQKREWTYYKL-UHFFFAOYSA-N 0.000 description 1
- FGLDUXYEVPKHOF-UHFFFAOYSA-N 2-(2-methoxyethoxy)pyridine-3-carboxylic acid Chemical compound COCCOC1=NC=CC=C1C(O)=O FGLDUXYEVPKHOF-UHFFFAOYSA-N 0.000 description 1
- XHWDFGQAXHSIMH-UHFFFAOYSA-N 2-(bromomethyl)-6-methoxypyridine Chemical compound COC1=CC=CC(CBr)=N1 XHWDFGQAXHSIMH-UHFFFAOYSA-N 0.000 description 1
- QFLPSIUFCCCRMI-UHFFFAOYSA-N 2-(chloromethyl)-6-methylpyridine;hydron;chloride Chemical compound Cl.CC1=CC=CC(CCl)=N1 QFLPSIUFCCCRMI-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- MSFVEEFXECBJPG-UHFFFAOYSA-N 2-(chloromethyl)pyrimidine Chemical compound ClCC1=NC=CC=N1 MSFVEEFXECBJPG-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- XZPUJJBQICGFDE-UHFFFAOYSA-N 2-[(1-methylimidazol-2-yl)methyl]-4-nitro-5-propylpyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(CCC)=NN1CC1=NC=CN1C XZPUJJBQICGFDE-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- IWNFNCWNRRHIEJ-UHFFFAOYSA-N 2-benzyl-3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC=4C=CC=CC=4)C(CC)=C3N=2)=C1 IWNFNCWNRRHIEJ-UHFFFAOYSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 1
- VHLUTFOZWGXTMJ-UHFFFAOYSA-N 2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carbonyl chloride;hydrochloride Chemical compound Cl.C1=C(C(Cl)=O)C(OCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 VHLUTFOZWGXTMJ-UHFFFAOYSA-N 0.000 description 1
- PCRIWLRXFJTJPJ-UHFFFAOYSA-N 2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(OCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 PCRIWLRXFJTJPJ-UHFFFAOYSA-N 0.000 description 1
- BAMZNZYNJQVZPD-UHFFFAOYSA-N 2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylpyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.C1=C(C(O)=O)C(OCC)=NC=C1S(=O)(=O)N1CCN(C)CC1 BAMZNZYNJQVZPD-UHFFFAOYSA-N 0.000 description 1
- GLSREOLUIPGEMD-UHFFFAOYSA-N 2-ethoxy-5-nitropyridine-3-carboxylic acid Chemical compound CCOC1=NC=C([N+]([O-])=O)C=C1C(O)=O GLSREOLUIPGEMD-UHFFFAOYSA-N 0.000 description 1
- XCMJQQOMGWGGSI-UHFFFAOYSA-N 2-ethoxypyridine-3-carboxylic acid Chemical compound CCOC1=NC=CC=C1C(O)=O XCMJQQOMGWGGSI-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- WIMNZMOEBDPZTB-UHFFFAOYSA-N 2-methoxy-6-methylpyridine Chemical compound COC1=CC=CC(C)=N1 WIMNZMOEBDPZTB-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- YTTFFPATQICAQN-UHFFFAOYSA-N 2-methoxypropan-1-ol Chemical compound COC(C)CO YTTFFPATQICAQN-UHFFFAOYSA-N 0.000 description 1
- MYMAJXSTADRYOZ-UHFFFAOYSA-N 2-methyl-1-oxidopyrimidin-1-ium Chemical compound CC1=NC=CC=[N+]1[O-] MYMAJXSTADRYOZ-UHFFFAOYSA-N 0.000 description 1
- NCNHKGZVJKQTMB-UHFFFAOYSA-N 2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=CNC(=O)C2=NN(C)C=C21 NCNHKGZVJKQTMB-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- KYBCXTTWIOZBNR-UHFFFAOYSA-N 2-piperazin-1-yl-1-pyrrolidin-1-ylethanone Chemical compound C1CCCN1C(=O)CN1CCNCC1 KYBCXTTWIOZBNR-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- UETCSFANSYKLNJ-UHFFFAOYSA-N 2-propoxypyridine-3-carboxylic acid Chemical compound CCCOC1=NC=CC=C1C(O)=O UETCSFANSYKLNJ-UHFFFAOYSA-N 0.000 description 1
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
- CNYDPKJPMBRDPE-UHFFFAOYSA-N 3-(2-phenylethenyl)pyridazine Chemical compound C=1C=CC=CC=1C=CC1=CC=CN=N1 CNYDPKJPMBRDPE-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- LPKSYVXQAWQCSP-UHFFFAOYSA-N 3-(chloromethyl)pyridazine;hydrochloride Chemical compound Cl.ClCC1=CC=CN=N1 LPKSYVXQAWQCSP-UHFFFAOYSA-N 0.000 description 1
- YLQRVYAPANMMHL-UHFFFAOYSA-N 3-bromo-5-(4-ethylpiperazin-1-yl)sulfonyl-n-propylpyridin-2-amine Chemical compound C1=C(Br)C(NCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 YLQRVYAPANMMHL-UHFFFAOYSA-N 0.000 description 1
- FFKCJOGBORRTLF-UHFFFAOYSA-N 3-ethyl-5-[2-(1-methoxypropan-2-yloxy)-5-(4-pyridin-2-ylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCC=1N(C)N=C(C(N2)=O)C=1N=C2C(C(=NC=1)OC(C)COC)=CC=1S(=O)(=O)N(CC1)CCN1C1=CC=CC=N1 FFKCJOGBORRTLF-UHFFFAOYSA-N 0.000 description 1
- ZXBVSPZDRHUVDY-UHFFFAOYSA-N 3-ethyl-5-[2-(2-methoxyethoxy)-5-(3,4,5-trimethylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CC(C)N(C)C(C)C3)OCCOC)=O)C2=C(CC)N1CC1=CC=CC=N1 ZXBVSPZDRHUVDY-UHFFFAOYSA-N 0.000 description 1
- KYJREMMUMYPUSN-UHFFFAOYSA-N 3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-propan-2-ylpiperazin-1-yl)sulfonylpyridin-3-yl]-6-methyl-2-pyridin-2-ylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound C(C)C=1N(N=C2C=1N=C(N(C2=O)C)C=1C(=NC=C(C=1)S(=O)(=O)N1CCN(CC1)C(C)C)OCCOC)C1=NC=CC=C1 KYJREMMUMYPUSN-UHFFFAOYSA-N 0.000 description 1
- DYHTWWUOQTWPRO-UHFFFAOYSA-N 3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-propylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CCC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=C1 DYHTWWUOQTWPRO-UHFFFAOYSA-N 0.000 description 1
- UGDFPTKNULAOIM-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-[(1-oxidopyridin-1-ium-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CC[N+]([O-])(CC)CC3)OCCOC)=O)C2=C(CC)N1CC1=CC=CC=[N+]1[O-] UGDFPTKNULAOIM-UHFFFAOYSA-N 0.000 description 1
- YQSJUBYNVPDPAD-OAHLLOKOSA-N 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-[(2r)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCC=1N(C)N=C(C(N2)=O)C=1N=C2C(C(=NC=1)O[C@H](C)COC)=CC=1S(=O)(=O)N1CC[N+]([O-])(CC)CC1 YQSJUBYNVPDPAD-OAHLLOKOSA-N 0.000 description 1
- ASHPUTDXVQEIPH-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-hydroxyethoxy)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCO)C(C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=C1 ASHPUTDXVQEIPH-UHFFFAOYSA-N 0.000 description 1
- MODJDVRRGPJLHG-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-1-[(1-methylimidazol-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C=3N(CC=4N(C=CN=4)C)N=C(CC)C=3N=2)=C1 MODJDVRRGPJLHG-UHFFFAOYSA-N 0.000 description 1
- MGDODSOYIMVTRE-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-[(1-methylimidazol-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC=4N(C=CN=4)C)C(CC)=C3N=2)=C1 MGDODSOYIMVTRE-UHFFFAOYSA-N 0.000 description 1
- SIKARGZTKNOAOF-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-[(6-methylpyridin-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC=4N=C(C)C=CC=4)C(CC)=C3N=2)=C1 SIKARGZTKNOAOF-UHFFFAOYSA-N 0.000 description 1
- BHCMQHZDKITWCF-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethylamino)pyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(NCCOC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 BHCMQHZDKITWCF-UHFFFAOYSA-N 0.000 description 1
- TVTNJZOLQQJMCN-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(3-methoxypropoxy)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCCOC)C(C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=C1 TVTNJZOLQQJMCN-UHFFFAOYSA-N 0.000 description 1
- BWMZSNIYOZKGFE-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(propylamino)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCNC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CC=N1 BWMZSNIYOZKGFE-UHFFFAOYSA-N 0.000 description 1
- SNZGUOSLIMLBLY-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(pyridin-2-ylmethoxy)pyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=CN=C1OCC1=CC=CC=N1 SNZGUOSLIMLBLY-UHFFFAOYSA-N 0.000 description 1
- PYQGGTKFEVRWAC-OAHLLOKOSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2r)-1-methoxypropan-2-yl]oxypyridin-3-yl]-1-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@H](C)COC)C(C=2NC(=O)C=3N(C)N=C(CC)C=3N=2)=C1 PYQGGTKFEVRWAC-OAHLLOKOSA-N 0.000 description 1
- KAQQXKVYHIXFRD-HXUWFJFHSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2r)-1-methoxypropan-2-yl]oxypyridin-3-yl]-6-methyl-2-(6-methylpyridin-2-yl)pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@H](C)COC)C(C=2N(C(=O)C3=NN(C(CC)=C3N=2)C=2N=C(C)C=CC=2)C)=C1 KAQQXKVYHIXFRD-HXUWFJFHSA-N 0.000 description 1
- XGFUANBFFASCQV-HZPDHXFCSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2r,3r)-3-methoxybutan-2-yl]oxypyridin-3-yl]-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@H](C)[C@@H](C)OC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 XGFUANBFFASCQV-HZPDHXFCSA-N 0.000 description 1
- AXJKWRLSLUKVML-IBGZPJMESA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(2s)-1-methoxypropan-2-yl]oxypyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(O[C@@H](C)COC)C(C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=C1 AXJKWRLSLUKVML-IBGZPJMESA-N 0.000 description 1
- JXEBZAJZTUYAEC-FQEVSTJZSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(3s)-oxolan-3-yl]oxypyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1C=2NC3=C(CC)N(CC=4N=CC=CC=4)N=C3C(=O)N=2)=CN=C1O[C@@H]1COCC1 JXEBZAJZTUYAEC-FQEVSTJZSA-N 0.000 description 1
- HPXFQMBUAHCNAP-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-phenylmethoxypyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=CN=C1OCC1=CC=CC=C1 HPXFQMBUAHCNAP-UHFFFAOYSA-N 0.000 description 1
- HJKCIBNRGOAPJB-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propan-2-yloxypyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OC(C)C)C(C=2NC3=C(CC)N(CC=4N=CC=CC=4)N=C3C(=O)N=2)=C1 HJKCIBNRGOAPJB-UHFFFAOYSA-N 0.000 description 1
- JSKHBJWGWWJRQA-UHFFFAOYSA-N 3-ethyl-5-[5-(4-methylpiperazin-1-yl)sulfonyl-2-propan-2-yloxypyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(N=C(N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OC(C)C)=O)C2=C(CC)N1CC1=CC=CC=N1 JSKHBJWGWWJRQA-UHFFFAOYSA-N 0.000 description 1
- MXDRPNGTQDRKQM-UHFFFAOYSA-N 3-methylpyridazine Chemical compound CC1=CC=CN=N1 MXDRPNGTQDRKQM-UHFFFAOYSA-N 0.000 description 1
- LWEOFVINMVZGAS-UHFFFAOYSA-N 3-piperazin-1-ylpropan-1-ol Chemical compound OCCCN1CCNCC1 LWEOFVINMVZGAS-UHFFFAOYSA-N 0.000 description 1
- HGDDHXWVBSKFTI-UHFFFAOYSA-N 3-tert-butyl-5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-1-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C=12)=NC=1C(C(C)(C)C)=NN2CC1=CC=CC=N1 HGDDHXWVBSKFTI-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- SXMKWESUHLVOEV-UHFFFAOYSA-N 4-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CC)CCN1S(=O)(=O)C1=CC=NC(OCCOC)=C1C(O)=O SXMKWESUHLVOEV-UHFFFAOYSA-N 0.000 description 1
- SUEPYQHCCAHCBO-UHFFFAOYSA-N 4-amino-1,5-diethylpyrazole-3-carboxamide Chemical compound CCC1=C(N)C(C(N)=O)=NN1CC SUEPYQHCCAHCBO-UHFFFAOYSA-N 0.000 description 1
- GSHQRYMDQVPVSL-UHFFFAOYSA-N 4-amino-1-[(1-methylimidazol-2-yl)methyl]-5-propylpyrazole-3-carboxamide Chemical compound CCCC1=C(N)C(C(N)=O)=NN1CC1=NC=CN1C GSHQRYMDQVPVSL-UHFFFAOYSA-N 0.000 description 1
- JGKDQVJWIHMUCZ-UHFFFAOYSA-N 4-amino-1-benzyl-5-ethylpyrazole-3-carboxamide Chemical compound CCC1=C(N)C(C(N)=O)=NN1CC1=CC=CC=C1 JGKDQVJWIHMUCZ-UHFFFAOYSA-N 0.000 description 1
- PZMXDLWWQHYXGY-UHFFFAOYSA-N 4-amino-1-methyl-3-propylpyrazole-5-carboxamide Chemical compound CCCC1=NN(C)C(C(N)=O)=C1N PZMXDLWWQHYXGY-UHFFFAOYSA-N 0.000 description 1
- JTJPGTZETAVXAY-UHFFFAOYSA-N 4-amino-1-methyl-5-propylpyrazole-3-carboxamide Chemical compound CCCC1=C(N)C(C(N)=O)=NN1C JTJPGTZETAVXAY-UHFFFAOYSA-N 0.000 description 1
- JVXDFTZWKFHULK-UHFFFAOYSA-N 4-amino-1h-pyrazole-5-carboxamide Chemical class NC(=O)C=1NN=CC=1N JVXDFTZWKFHULK-UHFFFAOYSA-N 0.000 description 1
- MSCGAWOQLDQCBT-UHFFFAOYSA-N 4-amino-2-[(1-methylimidazol-2-yl)methyl]-5-propylpyrazole-3-carboxamide Chemical compound NC(=O)C1=C(N)C(CCC)=NN1CC1=NC=CN1C MSCGAWOQLDQCBT-UHFFFAOYSA-N 0.000 description 1
- UCYSPAFCTNOUFA-UHFFFAOYSA-N 4-amino-5-ethyl-1-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound CCC1=C(N)C(C(N)=O)=NN1CC1=CC=CC=N1 UCYSPAFCTNOUFA-UHFFFAOYSA-N 0.000 description 1
- YWVSIIAAZLIBNQ-UHFFFAOYSA-N 4-amino-5-ethyl-1-[(1-methylimidazol-2-yl)methyl]pyrazole-3-carboxamide Chemical compound CCC1=C(N)C(C(N)=O)=NN1CC1=NC=CN1C YWVSIIAAZLIBNQ-UHFFFAOYSA-N 0.000 description 1
- ZVVNGCZZXMLAOA-UHFFFAOYSA-N 4-amino-5-ethyl-1-methylpyrazole-3-carboxamide Chemical compound CCC1=C(N)C(C(N)=O)=NN1C ZVVNGCZZXMLAOA-UHFFFAOYSA-N 0.000 description 1
- SPJTZZADVBWLAC-UHFFFAOYSA-N 4-amino-5-ethyl-2-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C(N)C(CC)=NN1CC1=CC=CC=N1 SPJTZZADVBWLAC-UHFFFAOYSA-N 0.000 description 1
- ZQLAKHCYIYBAMF-UHFFFAOYSA-N 4-amino-5-ethyl-2-[(1-methylimidazol-2-yl)methyl]pyrazole-3-carboxamide Chemical compound NC(=O)C1=C(N)C(CC)=NN1CC1=NC=CN1C ZQLAKHCYIYBAMF-UHFFFAOYSA-N 0.000 description 1
- DXSQCQUPVAUDDU-UHFFFAOYSA-N 4-amino-5-ethyl-2-methylpyrazole-3-carboxamide Chemical compound CCC1=NN(C)C(C(N)=O)=C1N DXSQCQUPVAUDDU-UHFFFAOYSA-N 0.000 description 1
- MYBKQIUKVJEVPG-UHFFFAOYSA-N 4-amino-5-propyl-1-(pyridazin-3-ylmethyl)pyrazole-3-carboxamide Chemical compound CCCC1=C(N)C(C(N)=O)=NN1CC1=CC=CN=N1 MYBKQIUKVJEVPG-UHFFFAOYSA-N 0.000 description 1
- RLJSXIFVMSWTAH-UHFFFAOYSA-N 4-amino-5-propyl-1-(pyrimidin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound CCCC1=C(N)C(C(N)=O)=NN1CC1=NC=CC=N1 RLJSXIFVMSWTAH-UHFFFAOYSA-N 0.000 description 1
- ZYUBHFQBCBGCTP-UHFFFAOYSA-N 4-amino-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCC1=NNC(C(N)=O)=C1N ZYUBHFQBCBGCTP-UHFFFAOYSA-N 0.000 description 1
- KQEMOQIENGSVOW-UHFFFAOYSA-N 4-amino-5-propyl-2-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C(N)C(CCC)=NN1CC1=CC=CC=N1 KQEMOQIENGSVOW-UHFFFAOYSA-N 0.000 description 1
- CNSYHNAMUIMAAQ-UHFFFAOYSA-N 4-amino-5-propyl-2-(pyrimidin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C(N)C(CCC)=NN1CC1=NC=CC=N1 CNSYHNAMUIMAAQ-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- METPUBMTPUYMGR-UHFFFAOYSA-N 4-methoxybutan-2-ol Chemical compound COCCC(C)O METPUBMTPUYMGR-UHFFFAOYSA-N 0.000 description 1
- JKUHDXIFOAUHBC-UHFFFAOYSA-N 4-nitro-5-propyl-1-(pyridazin-3-ylmethyl)pyrazole-3-carboxamide Chemical compound CCCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CN=N1 JKUHDXIFOAUHBC-UHFFFAOYSA-N 0.000 description 1
- PMSLZZQGJMTQNE-UHFFFAOYSA-N 4-nitro-5-propyl-1-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound CCCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CC=N1 PMSLZZQGJMTQNE-UHFFFAOYSA-N 0.000 description 1
- OEOQYHINYSQQOO-UHFFFAOYSA-N 4-nitro-5-propyl-1h-pyrazole-3-carboxamide Chemical compound CCCC1=NNC(C(N)=O)=C1[N+]([O-])=O OEOQYHINYSQQOO-UHFFFAOYSA-N 0.000 description 1
- WTLTYNIWFANVBQ-UHFFFAOYSA-N 4-nitro-5-propyl-1h-pyrazole-3-carboxylic acid Chemical compound CCCC=1NN=C(C(O)=O)C=1[N+]([O-])=O WTLTYNIWFANVBQ-UHFFFAOYSA-N 0.000 description 1
- NRICZAPNYDLULH-UHFFFAOYSA-N 4-nitro-5-propyl-2-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(CCC)=NN1CC1=CC=CC=N1 NRICZAPNYDLULH-UHFFFAOYSA-N 0.000 description 1
- QTPLZVLYNYGXRE-UHFFFAOYSA-N 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridine-3-carbonyl chloride;hydrochloride Chemical compound Cl.C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C(Cl)=O)=C1 QTPLZVLYNYGXRE-UHFFFAOYSA-N 0.000 description 1
- DFLDCTQBMHVGAF-UHFFFAOYSA-N 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-phenylmethoxyethoxy)pyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CC)CCN1S(=O)(=O)C(C=C1C(O)=O)=CN=C1OCCOCC1=CC=CC=C1 DFLDCTQBMHVGAF-UHFFFAOYSA-N 0.000 description 1
- LEBCLEZNLUEJKE-UHFFFAOYSA-N 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(3-methoxypropoxy)pyridine-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCCOC)C(C(O)=O)=C1 LEBCLEZNLUEJKE-UHFFFAOYSA-N 0.000 description 1
- OQSBPFOBJWDRIN-UHFFFAOYSA-N 5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxypyridine-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(OCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 OQSBPFOBJWDRIN-UHFFFAOYSA-N 0.000 description 1
- PZZGSGKDSHOHSD-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxypyridine-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(OCCC)=NC=C1S(=O)(=O)N1CCN(C)CC1 PZZGSGKDSHOHSD-UHFFFAOYSA-N 0.000 description 1
- KCNDEMGPDXJQKS-UHFFFAOYSA-N 5-[2-(1,3-dimethoxypropan-2-yloxy)-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-6-methyl-3-propyl-2-pyridin-2-ylpyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC=1N(C=2N=CC=CC=2)N=C(C(N2C)=O)C=1N=C2C(C(=NC=1)OC(COC)COC)=CC=1S(=O)(=O)N1CCN(CC)CC1 KCNDEMGPDXJQKS-UHFFFAOYSA-N 0.000 description 1
- XPKYEUYRTYWAPQ-UHFFFAOYSA-N 5-[2-(2-ethoxyethoxy)-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOCCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CC=N1 XPKYEUYRTYWAPQ-UHFFFAOYSA-N 0.000 description 1
- OAJNRYSYTSUIKH-OAHLLOKOSA-N 5-[2-[(2r)-butan-2-yl]oxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)C(O[C@H](C)CC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 OAJNRYSYTSUIKH-OAHLLOKOSA-N 0.000 description 1
- XLPGWSGZSGCIKF-UHFFFAOYSA-N 5-[2-[2-(dimethylamino)ethoxy]-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCCN(C)C)=O)C2=C(CCC)N1CC1=CC=CC=N1 XLPGWSGZSGCIKF-UHFFFAOYSA-N 0.000 description 1
- UPZHXMDFQQOKHG-UHFFFAOYSA-N 5-[2-[cyclopropylmethyl(methyl)amino]-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=CN=C1N(C)CC1CC1 UPZHXMDFQQOKHG-UHFFFAOYSA-N 0.000 description 1
- VRPIIMWKENPTNQ-UHFFFAOYSA-N 5-[2-butoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-2,3-diethyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(CC)C(CC)=C3N=2)C(OCCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 VRPIIMWKENPTNQ-UHFFFAOYSA-N 0.000 description 1
- IDDOPONOKDYAHJ-UHFFFAOYSA-N 5-[2-butoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-[(1-methylimidazol-2-yl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=NC=CN1C IDDOPONOKDYAHJ-UHFFFAOYSA-N 0.000 description 1
- NLFAUWDURSKVIE-UHFFFAOYSA-N 5-[2-butoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(C)C(CCC)=C3N=2)C(OCCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 NLFAUWDURSKVIE-UHFFFAOYSA-N 0.000 description 1
- LBKZYYGSCWKPJZ-UHFFFAOYSA-N 5-[2-butoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridazin-3-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CN=N1 LBKZYYGSCWKPJZ-UHFFFAOYSA-N 0.000 description 1
- RFRASFLNOATOPO-UHFFFAOYSA-N 5-[2-cyclobutyloxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C(C=C1C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=CN=C1OC1CCC1 RFRASFLNOATOPO-UHFFFAOYSA-N 0.000 description 1
- DVPIQVPCUMSSIS-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonylpyridin-3-yl]-2-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC=1N(C)N=C(C(N2)=O)C=1N=C2C(C(=NC=1)OCC)=CC=1S(=O)(=O)N1CC[N+]([O-])(CC)CC1 DVPIQVPCUMSSIS-UHFFFAOYSA-N 0.000 description 1
- CZAYWCHYRACWIC-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CC[N+]([O-])(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CC=N1 CZAYWCHYRACWIC-UHFFFAOYSA-N 0.000 description 1
- IKBWBHIHILGVHH-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=NC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 IKBWBHIHILGVHH-UHFFFAOYSA-N 0.000 description 1
- OYOYXQUUXJWVEW-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-1-[(1-methylimidazol-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C=12)=NC=1C(CC)=NN2CC1=NC=CN1C OYOYXQUUXJWVEW-UHFFFAOYSA-N 0.000 description 1
- PHTNNWQOSLPLPE-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridazin-3-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CN=N1 PHTNNWQOSLPLPE-UHFFFAOYSA-N 0.000 description 1
- KLWPHBJVDIKHQL-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=CC=CC=N1 KLWPHBJVDIKHQL-UHFFFAOYSA-N 0.000 description 1
- LNBOAIZWBCFWRH-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-[(1-methylimidazol-2-yl)methyl]-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CC)N2CC1=NC=CN1C LNBOAIZWBCFWRH-UHFFFAOYSA-N 0.000 description 1
- VKSUMLPUSYUBDS-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-1-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=NC=C(C=2)S(=O)(=O)N2CCN(CC)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=CC=CC=N1 VKSUMLPUSYUBDS-UHFFFAOYSA-N 0.000 description 1
- NVJXZSUMCFZOPH-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-1-(pyrimidin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=NC=C(C=2)S(=O)(=O)N2CCN(CC)CC2)OCC)NC(=O)C2=C1C(CCC)=NN2CC1=NC=CC=N1 NVJXZSUMCFZOPH-UHFFFAOYSA-N 0.000 description 1
- RXCOEYABNLBNNA-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=CC=N1 RXCOEYABNLBNNA-UHFFFAOYSA-N 0.000 description 1
- HKXPRNOEZIEWTH-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-2-(pyrimidin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCC)=O)C2=C(CCC)N1CC1=NC=CC=N1 HKXPRNOEZIEWTH-UHFFFAOYSA-N 0.000 description 1
- FVSSQRXZYHAQSQ-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC=1N(C)N=C(C(N2)=O)C=1N=C2C(C(=NC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 FVSSQRXZYHAQSQ-UHFFFAOYSA-N 0.000 description 1
- MCOZURKPAICFRE-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(C)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=CC=N1 MCOZURKPAICFRE-UHFFFAOYSA-N 0.000 description 1
- BGYFRYVOHKBWMS-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-propan-2-ylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)C(OCC)=NC=C1S(=O)(=O)N1CCN(C(C)C)CC1 BGYFRYVOHKBWMS-UHFFFAOYSA-N 0.000 description 1
- LDMCKVNUTBGNPK-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-propylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CCC)CCN1S(=O)(=O)C1=CN=C(OCC)C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)=C1 LDMCKVNUTBGNPK-UHFFFAOYSA-N 0.000 description 1
- GZMCALIILFNLME-UHFFFAOYSA-N 5-[2-ethoxy-5-(4-pyridin-2-ylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-methyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1=C(C=2NC(=O)C3=NN(C)C(CC)=C3N=2)C(OCC)=NC=C1S(=O)(=O)N(CC1)CCN1C1=CC=CC=N1 GZMCALIILFNLME-UHFFFAOYSA-N 0.000 description 1
- IWWZTBZNTQEOPG-UHFFFAOYSA-N 5-[2-ethoxy-5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonylpyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CCO)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=CC=N1 IWWZTBZNTQEOPG-UHFFFAOYSA-N 0.000 description 1
- ROMKYHXCAUSFTG-UHFFFAOYSA-N 5-[2-ethoxy-5-[4-(3-hydroxypropyl)piperazin-1-yl]sulfonylpyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CCCO)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=CC=N1 ROMKYHXCAUSFTG-UHFFFAOYSA-N 0.000 description 1
- AUSIAWUXFRHKBP-UHFFFAOYSA-N 5-[3-ethyl-7-oxo-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-5-yl]-6-(2-methoxyethoxy)pyridine-3-sulfonyl chloride Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(Cl)(=O)=O)OCCOC)=O)C2=C(CC)N1CC1=CC=CC=N1 AUSIAWUXFRHKBP-UHFFFAOYSA-N 0.000 description 1
- AJKWZYSISSJONU-UHFFFAOYSA-N 5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=NC=1)OCCOC)=CC=1S(=O)(=O)N1CC[N+]([O-])(CC)CC1 AJKWZYSISSJONU-UHFFFAOYSA-N 0.000 description 1
- QANPXUQSLCNXMX-UHFFFAOYSA-N 5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC=1N(C)N=C(C(N2)=O)C=1N=C2C(C(=NC=1)OCCOC)=CC=1S(=O)(=O)N1CC[N+]([O-])(CC)CC1 QANPXUQSLCNXMX-UHFFFAOYSA-N 0.000 description 1
- DGZHRFDBVJNMIA-UHFFFAOYSA-N 5-[5-(4-ethyl-4-oxidopiperazin-4-ium-1-yl)sulfonyl-2-propoxypyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=NC=C(S(=O)(=O)N2CC[N+]([O-])(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CC=CC=N1 DGZHRFDBVJNMIA-UHFFFAOYSA-N 0.000 description 1
- LNWCRSNHCABILC-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methylpiperidin-4-yl)oxypyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OC3CCN(C)CC3)=O)C2=C(CCC)N1CC1=CC=CC=N1 LNWCRSNHCABILC-UHFFFAOYSA-N 0.000 description 1
- GCBIDSVOSKPWHG-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-1-[(1-methylimidazol-2-yl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=NC=C(C=2)S(=O)(=O)N2CCN(CC)CC2)OCCOC)NC(=O)C2=C1C(CCC)=NN2CC1=NC=CN1C GCBIDSVOSKPWHG-UHFFFAOYSA-N 0.000 description 1
- TUQLALUIGFAPNS-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=NC=1)OCCOC)=CC=1S(=O)(=O)N1CCN(CC)CC1 TUQLALUIGFAPNS-UHFFFAOYSA-N 0.000 description 1
- WUTGHTKHPNMTTA-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-[(1-methylimidazol-2-yl)methyl]-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCCOC)=O)C2=C(CCC)N1CC1=NC=CN1C WUTGHTKHPNMTTA-UHFFFAOYSA-N 0.000 description 1
- UKQLJXOEIRGEIY-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-3-propyl-1-(pyrimidin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C=2C(=NC=C(C=2)S(=O)(=O)N2CCN(CC)CC2)OCCOC)NC(=O)C2=C1C(CCC)=NN2CC1=NC=CC=N1 UKQLJXOEIRGEIY-UHFFFAOYSA-N 0.000 description 1
- APRREPRXFZRXQK-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-3-propyl-2-(pyrimidin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCCOC)=O)C2=C(CCC)N1CC1=NC=CC=N1 APRREPRXFZRXQK-UHFFFAOYSA-N 0.000 description 1
- WBCHEODFTIWVTD-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-phenylmethoxyethoxy)pyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCCOCC=3C=CC=CC=3)=O)C2=C(CCC)N1CC1=CC=CC=N1 WBCHEODFTIWVTD-UHFFFAOYSA-N 0.000 description 1
- MDRFTZUHROBTTC-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(furan-3-ylmethoxy)pyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OCC3=COC=C3)=O)C2=C(CCC)N1CC1=CC=CC=N1 MDRFTZUHROBTTC-UHFFFAOYSA-N 0.000 description 1
- KFJHLGKQQCTVHK-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(oxan-4-yloxy)pyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OC3CCOCC3)=O)C2=C(CCC)N1CC1=CC=CC=N1 KFJHLGKQQCTVHK-UHFFFAOYSA-N 0.000 description 1
- SAKBUPJVCUPQQJ-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(pyridin-2-ylmethoxy)pyridin-3-yl]-1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C1=CC(S(=O)(=O)N2CCN(CC)CC2)=CN=C1OCC1=CC=CC=N1 SAKBUPJVCUPQQJ-UHFFFAOYSA-N 0.000 description 1
- WIEXCFHYLUXDOE-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propan-2-yloxypyridin-3-yl]-3-propyl-2-(pyridazin-3-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OC(C)C)=O)C2=C(CCC)N1CC1=CC=CN=N1 WIEXCFHYLUXDOE-UHFFFAOYSA-N 0.000 description 1
- RJSQLUQNMMJTAH-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propan-2-yloxypyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CC)CC3)OC(C)C)=O)C2=C(CCC)N1CC1=CC=CC=N1 RJSQLUQNMMJTAH-UHFFFAOYSA-N 0.000 description 1
- FVXAZZZMYUEJPT-UHFFFAOYSA-N 5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxypyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound CCCOC1=NC=C(S(=O)(=O)N2CCN(CC)CC2)C=C1C(NC(=O)C1=N2)=NC1=C(CCC)N2CC1=CC=CC=N1 FVXAZZZMYUEJPT-UHFFFAOYSA-N 0.000 description 1
- IYVOBOBNUXUIPX-UHFFFAOYSA-N 5-[5-[4-[3-(dimethylamino)propyl]piperazin-1-yl]sulfonyl-2-ethoxypyridin-3-yl]-3-propyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one;trihydrochloride Chemical compound Cl.Cl.Cl.N1=C(C(NC(=N2)C=3C(=NC=C(C=3)S(=O)(=O)N3CCN(CCCN(C)C)CC3)OCC)=O)C2=C(CCC)N1CC1=CC=CC=N1 IYVOBOBNUXUIPX-UHFFFAOYSA-N 0.000 description 1
- CMVKEVDEFXNMGS-UHFFFAOYSA-N 5-[5-amino-2-(2-methoxyethoxy)pyridin-3-yl]-3-ethyl-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=C(C(NC(=N2)C=3C(=NC=C(N)C=3)OCCOC)=O)C2=C(CC)N1CC1=CC=CC=N1 CMVKEVDEFXNMGS-UHFFFAOYSA-N 0.000 description 1
- TURGMVYIESHZBE-UHFFFAOYSA-N 5-bromo-6-chloropyridine-3-sulfonyl chloride Chemical compound ClC1=NC=C(S(Cl)(=O)=O)C=C1Br TURGMVYIESHZBE-UHFFFAOYSA-N 0.000 description 1
- MCPYFJRFLSZZCL-UHFFFAOYSA-N 5-ethyl-1-[(1-methylimidazol-2-yl)methyl]-4-nitropyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=NC=CN1C MCPYFJRFLSZZCL-UHFFFAOYSA-N 0.000 description 1
- AVSYJIXONLTOMP-UHFFFAOYSA-N 5-ethyl-1-[(6-methoxypyridin-2-yl)methyl]-4-nitropyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CC(OC)=N1 AVSYJIXONLTOMP-UHFFFAOYSA-N 0.000 description 1
- TYFJCZLQWJPIHX-UHFFFAOYSA-N 5-ethyl-1-[(6-methylpyridin-2-yl)methyl]-4-nitropyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CC(C)=N1 TYFJCZLQWJPIHX-UHFFFAOYSA-N 0.000 description 1
- DYVHEQJLJMGEOF-UHFFFAOYSA-N 5-ethyl-1-methyl-4-nitropyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1C DYVHEQJLJMGEOF-UHFFFAOYSA-N 0.000 description 1
- WCQYJWRMYFJLRQ-UHFFFAOYSA-N 5-ethyl-1h-pyrazole-3-carboxylic acid Chemical compound CCC1=CC(C(O)=O)=NN1 WCQYJWRMYFJLRQ-UHFFFAOYSA-N 0.000 description 1
- YNFKKRBPJKIKHC-UHFFFAOYSA-N 5-ethyl-2-[(1-methylimidazol-2-yl)methyl]-4-nitropyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(CC)=NN1CC1=NC=CN1C YNFKKRBPJKIKHC-UHFFFAOYSA-N 0.000 description 1
- UPIGDYBRYFATDV-UHFFFAOYSA-N 5-ethyl-2-methyl-4-nitropyrazole-3-carboxamide Chemical compound CCC1=NN(C)C(C(N)=O)=C1[N+]([O-])=O UPIGDYBRYFATDV-UHFFFAOYSA-N 0.000 description 1
- FYLYGDDANMNHIF-UHFFFAOYSA-N 5-ethyl-4-nitro-1-(1-pyridin-2-ylethyl)pyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1C(C)C1=CC=CC=N1 FYLYGDDANMNHIF-UHFFFAOYSA-N 0.000 description 1
- CCOUPBHQFIUJRF-UHFFFAOYSA-N 5-ethyl-4-nitro-1-(pyridazin-3-ylmethyl)pyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CN=N1 CCOUPBHQFIUJRF-UHFFFAOYSA-N 0.000 description 1
- CJYBXEHWVOEQTG-UHFFFAOYSA-N 5-ethyl-4-nitro-1-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound CCC1=C([N+]([O-])=O)C(C(N)=O)=NN1CC1=CC=CC=N1 CJYBXEHWVOEQTG-UHFFFAOYSA-N 0.000 description 1
- XTPUQGFKKAURLH-UHFFFAOYSA-N 5-ethyl-4-nitro-1h-pyrazole-3-carboxamide Chemical compound CCC=1NN=C(C(N)=O)C=1[N+]([O-])=O XTPUQGFKKAURLH-UHFFFAOYSA-N 0.000 description 1
- UDYWTLMYXXTHKR-UHFFFAOYSA-N 5-ethyl-4-nitro-1h-pyrazole-3-carboxylic acid Chemical compound CCC=1NN=C(C(O)=O)C=1[N+]([O-])=O UDYWTLMYXXTHKR-UHFFFAOYSA-N 0.000 description 1
- QVUCIANTCGORTG-UHFFFAOYSA-N 5-ethyl-4-nitro-2-(pyridazin-3-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(CC)=NN1CC1=CC=CN=N1 QVUCIANTCGORTG-UHFFFAOYSA-N 0.000 description 1
- WXVLOIREJGHFAE-UHFFFAOYSA-N 5-ethyl-4-nitro-2-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(CC)=NN1CC1=CC=CC=N1 WXVLOIREJGHFAE-UHFFFAOYSA-N 0.000 description 1
- WRKWQCNJAZPEKK-UHFFFAOYSA-N 5-methyl-1h-pyrazole-3-carboxamide Chemical compound CC=1C=C(C(N)=O)NN=1 WRKWQCNJAZPEKK-UHFFFAOYSA-N 0.000 description 1
- MZRUFMBFIKGOAL-UHFFFAOYSA-N 5-nitro-1h-pyrazole Chemical class [O-][N+](=O)C1=CC=NN1 MZRUFMBFIKGOAL-UHFFFAOYSA-N 0.000 description 1
- QYPSYPPSHXDFLV-UHFFFAOYSA-N 5-propyl-1h-pyrazole-3-carboxylic acid Chemical compound CCCC1=CC(C(O)=O)=NN1 QYPSYPPSHXDFLV-UHFFFAOYSA-N 0.000 description 1
- LCHZQSLYWPECJX-UHFFFAOYSA-N 5-tert-butyl-1h-pyrazole-3-carboxylic acid;hydrochloride Chemical compound Cl.CC(C)(C)C=1C=C(C(O)=O)NN=1 LCHZQSLYWPECJX-UHFFFAOYSA-N 0.000 description 1
- OLPKIOKCWXMRHE-UHFFFAOYSA-N 5-tert-butyl-4-nitro-1h-pyrazole-3-carboxylic acid Chemical compound CC(C)(C)C1=NNC(C(O)=O)=C1[N+]([O-])=O OLPKIOKCWXMRHE-UHFFFAOYSA-N 0.000 description 1
- BRLIIDWXCQMWPY-UHFFFAOYSA-N 5-tert-butyl-4-nitro-2-(pyridin-2-ylmethyl)pyrazole-3-carboxamide Chemical compound NC(=O)C1=C([N+]([O-])=O)C(C(C)(C)C)=NN1CC1=CC=CC=N1 BRLIIDWXCQMWPY-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- AQPIHLQSXPSMHZ-UHFFFAOYSA-N 6-amino-5-bromopyridin-1-ium-3-sulfonate Chemical compound NC1=[NH+]C=C(S([O-])(=O)=O)C=C1Br AQPIHLQSXPSMHZ-UHFFFAOYSA-N 0.000 description 1
- YXFLGKSXYWHALA-UHFFFAOYSA-N 6-aminopyridine-3-sulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=N1 YXFLGKSXYWHALA-UHFFFAOYSA-N 0.000 description 1
- JEAVIRYCMBDJIU-UHFFFAOYSA-N 6-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CC(O)=N1 JEAVIRYCMBDJIU-UHFFFAOYSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- FDGHJELMRQGSTO-UHFFFAOYSA-N C1=C(C(O)=O)C(NCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 Chemical compound C1=C(C(O)=O)C(NCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 FDGHJELMRQGSTO-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- FDLIRSQTJLADCV-UHFFFAOYSA-N C[SiH2][N-][SiH2]C.[K+] Chemical compound C[SiH2][N-][SiH2]C.[K+] FDLIRSQTJLADCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 239000009975 Urodyn Substances 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000006241 alcohol protecting group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical class N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- OQRBCLLVAUWAKU-UHFFFAOYSA-L copper;sulfate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O OQRBCLLVAUWAKU-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 239000012971 dimethylpiperazine Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- RUCHDNJKZWSJHB-UHFFFAOYSA-N ethyl 1-methyl-5-propylpyrazole-3-carboxylate Chemical compound CCCC1=CC(C(=O)OCC)=NN1C RUCHDNJKZWSJHB-UHFFFAOYSA-N 0.000 description 1
- CRXLZXRQHKPEPI-UHFFFAOYSA-N ethyl 2-(1,3-dimethoxypropan-2-yloxy)-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carboxylate Chemical compound N1=C(OC(COC)COC)C(C(=O)OCC)=CC(S(=O)(=O)N2CCN(CC)CC2)=C1 CRXLZXRQHKPEPI-UHFFFAOYSA-N 0.000 description 1
- HCLAEHJOSXXVTN-UHFFFAOYSA-N ethyl 2-(2-ethoxyethoxy)-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carboxylate Chemical compound C1=C(C(=O)OCC)C(OCCOCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 HCLAEHJOSXXVTN-UHFFFAOYSA-N 0.000 description 1
- RAMPAHSDWDDYQU-UHFFFAOYSA-N ethyl 2-(2-methoxyethoxy)-5-nitropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC([N+]([O-])=O)=CN=C1OCCOC RAMPAHSDWDDYQU-UHFFFAOYSA-N 0.000 description 1
- CUTZNJFNVRXERH-UHFFFAOYSA-N ethyl 2-(2-methoxyethoxy)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1OCCOC CUTZNJFNVRXERH-UHFFFAOYSA-N 0.000 description 1
- YOXICXXCICYQKS-UHFFFAOYSA-N ethyl 2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carboxylate Chemical compound N1=C(OCC)C(C(=O)OCC)=CC(S(=O)(=O)N2CCN(CC)CC2)=C1 YOXICXXCICYQKS-UHFFFAOYSA-N 0.000 description 1
- ZFMHNOYNFAKUDY-UHFFFAOYSA-N ethyl 2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylpyridine-3-carboxylate Chemical compound N1=C(OCC)C(C(=O)OCC)=CC(S(=O)(=O)N2CCN(C)CC2)=C1 ZFMHNOYNFAKUDY-UHFFFAOYSA-N 0.000 description 1
- NRGZULIPVLBOHE-UHFFFAOYSA-N ethyl 2-ethoxy-5-nitropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC([N+]([O-])=O)=CN=C1OCC NRGZULIPVLBOHE-UHFFFAOYSA-N 0.000 description 1
- WJIBAKMAWMCQDU-UHFFFAOYSA-N ethyl 2-ethoxypyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1OCC WJIBAKMAWMCQDU-UHFFFAOYSA-N 0.000 description 1
- ZPSRHLWRTVNGSM-UHFFFAOYSA-N ethyl 2-methyl-5-propylpyrazole-3-carboxylate Chemical compound CCCC=1C=C(C(=O)OCC)N(C)N=1 ZPSRHLWRTVNGSM-UHFFFAOYSA-N 0.000 description 1
- NIMKIMUBJFWPTD-UHFFFAOYSA-N ethyl 5,5-dimethyl-2,4-dioxohexanoate Chemical compound CCOC(=O)C(=O)CC(=O)C(C)(C)C NIMKIMUBJFWPTD-UHFFFAOYSA-N 0.000 description 1
- CBCJCAKYANYTBJ-UHFFFAOYSA-N ethyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methylpiperidin-4-yl)oxypyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(=O)(=O)N2CCN(CC)CC2)=CN=C1OC1CCN(C)CC1 CBCJCAKYANYTBJ-UHFFFAOYSA-N 0.000 description 1
- IEGDGYGLWILZLJ-UHFFFAOYSA-N ethyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridine-3-carboxylate Chemical compound N1=C(OCCOC)C(C(=O)OCC)=CC(S(=O)(=O)N2CCN(CC)CC2)=C1 IEGDGYGLWILZLJ-UHFFFAOYSA-N 0.000 description 1
- OXOCYPHQWDXTBM-UHFFFAOYSA-N ethyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(3-methoxypropoxy)pyridine-3-carboxylate Chemical compound N1=C(OCCCOC)C(C(=O)OCC)=CC(S(=O)(=O)N2CCN(CC)CC2)=C1 OXOCYPHQWDXTBM-UHFFFAOYSA-N 0.000 description 1
- QLJKAEXRXFFQIC-UHFFFAOYSA-N ethyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-(oxan-4-yloxy)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(=O)(=O)N2CCN(CC)CC2)=CN=C1OC1CCOCC1 QLJKAEXRXFFQIC-UHFFFAOYSA-N 0.000 description 1
- XSNYQCXIGIJDQN-CQSZACIVSA-N ethyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(3r)-oxolan-3-yl]oxypyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(=O)(=O)N2CCN(CC)CC2)=CN=C1O[C@@H]1CCOC1 XSNYQCXIGIJDQN-CQSZACIVSA-N 0.000 description 1
- XSNYQCXIGIJDQN-AWEZNQCLSA-N ethyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-[(3s)-oxolan-3-yl]oxypyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(=O)(=O)N2CCN(CC)CC2)=CN=C1O[C@H]1CCOC1 XSNYQCXIGIJDQN-AWEZNQCLSA-N 0.000 description 1
- TZEXUTQSDJTATA-UHFFFAOYSA-N ethyl 5-amino-2-ethoxypyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(N)=CN=C1OCC TZEXUTQSDJTATA-UHFFFAOYSA-N 0.000 description 1
- YFONSBZEAHNVCW-UHFFFAOYSA-N ethyl 5-ethyl-1h-pyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(CC)NN=1 YFONSBZEAHNVCW-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- STJIISDMSMJQQK-UHFFFAOYSA-N furan-3-ylmethanol Chemical compound OCC=1C=COC=1 STJIISDMSMJQQK-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- IBTWUVRCFHJPKN-UHFFFAOYSA-N hydron;pyridine-3-carboxylic acid;chloride Chemical compound Cl.OC(=O)C1=CC=CN=C1 IBTWUVRCFHJPKN-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000007926 intracavernous injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- HRBRJUGUEMJODN-UHFFFAOYSA-N methanol pentane Chemical compound CO.CO.CCCCC HRBRJUGUEMJODN-UHFFFAOYSA-N 0.000 description 1
- MKCLFUHWBHMTRY-UHFFFAOYSA-N methyl 2-propoxypyridine-3-carboxylate Chemical compound CCCOC1=NC=CC=C1C(=O)OC MKCLFUHWBHMTRY-UHFFFAOYSA-N 0.000 description 1
- YJXPDYQUIWDXTI-UHFFFAOYSA-N methyl 5-(4-ethylpiperazin-1-yl)sulfonyl-2-propoxypyridine-3-carboxylate Chemical compound C1=C(C(=O)OC)C(OCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 YJXPDYQUIWDXTI-UHFFFAOYSA-N 0.000 description 1
- ILIZIRZNLURXBS-UHFFFAOYSA-N methyl 5-(4-methylpiperazin-1-yl)sulfonyl-2-propoxypyridine-3-carboxylate Chemical compound C1=C(C(=O)OC)C(OCCC)=NC=C1S(=O)(=O)N1CCN(C)CC1 ILIZIRZNLURXBS-UHFFFAOYSA-N 0.000 description 1
- ZGCWVTIIBZFVRV-UHFFFAOYSA-N methyl 5-amino-2-propoxypyridine-3-carboxylate Chemical compound CCCOC1=NC=C(N)C=C1C(=O)OC ZGCWVTIIBZFVRV-UHFFFAOYSA-N 0.000 description 1
- SBOLYFYRPOUEFU-UHFFFAOYSA-N methyl 5-nitro-2-propoxypyridine-3-carboxylate Chemical compound CCCOC1=NC=C([N+]([O-])=O)C=C1C(=O)OC SBOLYFYRPOUEFU-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- TTYMURDBXAIXQT-UHFFFAOYSA-N n'-(1,3-dichlorohexyl)methanediimine Chemical compound CCCC(Cl)CC(Cl)N=C=N TTYMURDBXAIXQT-UHFFFAOYSA-N 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- YJRGRZJKGMBHIB-UHFFFAOYSA-N n,n-dimethyl-3-piperazin-1-ylpropan-1-amine Chemical compound CN(C)CCCN1CCNCC1 YJRGRZJKGMBHIB-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 1
- BVNIREPGHLFKNZ-UHFFFAOYSA-N n-methylcyclopropanecarboxamide Chemical compound CNC(=O)C1CC1 BVNIREPGHLFKNZ-UHFFFAOYSA-N 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- STIKETVNLGXQCS-UHFFFAOYSA-N pyridazin-3-ylmethanol Chemical compound OCC1=CC=CN=N1 STIKETVNLGXQCS-UHFFFAOYSA-N 0.000 description 1
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- CFEXPOIGPXHNAM-UHFFFAOYSA-M sodium;2-(1,3-dimethoxypropan-2-yloxy)-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carboxylate Chemical compound [Na+].C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OC(COC)COC)C(C([O-])=O)=C1 CFEXPOIGPXHNAM-UHFFFAOYSA-M 0.000 description 1
- XZDHGSJSAAEMQB-UHFFFAOYSA-M sodium;2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridine-3-carboxylate Chemical compound [Na+].C1=C(C([O-])=O)C(OCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 XZDHGSJSAAEMQB-UHFFFAOYSA-M 0.000 description 1
- MVFQAAOBHFCZEU-UHFFFAOYSA-M sodium;5-(4-ethylpiperazin-1-yl)sulfonyl-2-(1-methylpiperidin-4-yl)oxypyridine-3-carboxylate Chemical compound [Na+].C1CN(CC)CCN1S(=O)(=O)C(C=C1C([O-])=O)=CN=C1OC1CCN(C)CC1 MVFQAAOBHFCZEU-UHFFFAOYSA-M 0.000 description 1
- QAUXNYQUWJTZGD-UHFFFAOYSA-M sodium;5-(4-ethylpiperazin-1-yl)sulfonyl-2-(oxan-4-yloxy)pyridine-3-carboxylate Chemical compound [Na+].C1CN(CC)CCN1S(=O)(=O)C(C=C1C([O-])=O)=CN=C1OC1CCOCC1 QAUXNYQUWJTZGD-UHFFFAOYSA-M 0.000 description 1
- YCOGRNHGLLVACL-UHFFFAOYSA-M sodium;5-(4-ethylpiperazin-1-yl)sulfonyl-2-(propylamino)pyridine-3-carboxylate Chemical compound [Na+].C1=C(C([O-])=O)C(NCCC)=NC=C1S(=O)(=O)N1CCN(CC)CC1 YCOGRNHGLLVACL-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9808315.7A GB9808315D0 (en) | 1998-04-20 | 1998-04-20 | Therapeutic agents |
GBGB9814187.2A GB9814187D0 (en) | 1998-06-30 | 1998-06-30 | Therapeutic agents |
PCT/IB1999/000519 WO1999054333A1 (en) | 1998-04-20 | 1999-03-25 | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000712A2 true HRP20000712A2 (en) | 2001-06-30 |
Family
ID=26313490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000712A HRP20000712A2 (en) | 1998-04-20 | 2000-10-20 | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
Country Status (40)
Country | Link |
---|---|
US (2) | US6251904B1 (es) |
EP (2) | EP1073658B1 (es) |
JP (2) | JP3721077B2 (es) |
KR (1) | KR100449790B1 (es) |
CN (2) | CN1229349C (es) |
AP (1) | AP1022A (es) |
AR (2) | AR015770A1 (es) |
AT (2) | ATE299503T1 (es) |
AU (1) | AU748352B2 (es) |
BG (1) | BG104949A (es) |
BR (1) | BR9909808A (es) |
CA (1) | CA2329077C (es) |
CO (1) | CO5271649A1 (es) |
DE (2) | DE69910368T2 (es) |
DK (2) | DK1073658T3 (es) |
DZ (1) | DZ2773A1 (es) |
EA (1) | EA200000969A1 (es) |
ES (2) | ES2242124T3 (es) |
GT (1) | GT199900053A (es) |
HK (1) | HK1064670A1 (es) |
HR (1) | HRP20000712A2 (es) |
HU (1) | HUP0102543A3 (es) |
ID (1) | ID27036A (es) |
IL (2) | IL138907A0 (es) |
IS (1) | IS5650A (es) |
MA (1) | MA26622A1 (es) |
NO (1) | NO20005255L (es) |
OA (1) | OA11502A (es) |
PA (1) | PA8470501A1 (es) |
PE (1) | PE20000463A1 (es) |
PL (1) | PL343794A1 (es) |
PT (2) | PT1073658E (es) |
RS (1) | RS50011B (es) |
SI (2) | SI1371647T1 (es) |
SK (1) | SK15532000A3 (es) |
TN (1) | TNSN99073A1 (es) |
TR (1) | TR200003039T2 (es) |
TW (1) | TW593310B (es) |
UY (1) | UY25484A1 (es) |
WO (1) | WO1999054333A1 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL336586A1 (en) | 1997-04-25 | 2000-07-03 | Pfizer | Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
HUP0102543A3 (en) * | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
US6242444B1 (en) | 1999-06-04 | 2001-06-05 | The Jordanian Pharmaceutical Manufacturing And Medical Equipment Co., Ltd. | Compounds and pharmaceutical compositions containing the same |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US6350751B1 (en) * | 1999-10-11 | 2002-02-26 | Pfizer Inc. | Therapeutic agents |
GB9924020D0 (en) | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Pharmaceutically active compounds |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
YU59100A (sh) * | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
GB9923968D0 (en) * | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Therapeutic agents |
EP1222190A1 (en) * | 1999-10-11 | 2002-07-17 | Pfizer Limited | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
JP2004500425A (ja) * | 2000-04-19 | 2004-01-08 | リリー アイコス リミテッド ライアビリティ カンパニー | パーキンソン病の処置に対する環状gmp特異的ホスホジエステラーゼインヒビターの使用 |
US6667398B2 (en) * | 2000-06-22 | 2003-12-23 | Pfizer Inc | Process for the preparation of pyrazolopyrimidinones |
US6730786B2 (en) | 2000-06-22 | 2004-05-04 | Pfizer Inc | Process for the preparation of pyrazolopyrimidinones |
US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6420557B1 (en) * | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
EE200300045A (et) * | 2000-07-28 | 2004-12-15 | Pfizer Inc. | Kristalne ravimaine |
US6809200B2 (en) * | 2000-07-28 | 2004-10-26 | Pfizer Inc. | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
GB0105893D0 (en) * | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
US6831074B2 (en) * | 2001-03-16 | 2004-12-14 | Pfizer Inc | Pharmaceutically active compounds |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
EP1442042A1 (en) | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
DK1348707T3 (da) * | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
WO2004096810A1 (en) | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
CN100374441C (zh) * | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途 |
US20050079548A1 (en) * | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
EP1708718A1 (en) | 2004-01-22 | 2006-10-11 | Pfizer Limited | Triazole derivatives which inhibit vasopressin antagonistic activity |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
WO2005097799A1 (en) | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3-d! pyrimidines |
CA2577442A1 (en) * | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
ATE412648T1 (de) | 2005-03-21 | 2008-11-15 | Pfizer Ltd | Substituierte triazolderivate als oxytocinantagonisten |
US20060235028A1 (en) * | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
ES2433661T3 (es) | 2005-04-19 | 2013-12-12 | Takeda Gmbh | Roflumilast para el tratamiento de hipertensión pulmonar |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008070095A1 (en) * | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
KR100989093B1 (ko) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물 |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
MX2010006227A (es) | 2010-06-07 | 2011-12-14 | World Trade Imp Exp Wtie Ag | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
US10899756B2 (en) | 2013-07-17 | 2021-01-26 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
EP3099689B1 (en) | 2014-01-30 | 2022-01-26 | Council of Scientific and Industrial Research | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof |
CN103922960B (zh) * | 2014-04-16 | 2015-10-21 | 浙江中山化工集团股份有限公司 | 一种s-异丙甲草胺的合成方法 |
CN104402811A (zh) * | 2014-11-11 | 2015-03-11 | 常州大学 | 一种合成二甲氨基吡啶甲酸的方法 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
KR102507967B1 (ko) | 2016-09-09 | 2023-03-09 | 인사이트 코포레이션 | Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도 |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
CN112313224A (zh) * | 2018-04-06 | 2021-02-02 | 黑带医疗有限责任公司 | Atf6抑制剂和其用途 |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871843A (en) | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
US4663326A (en) | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
US5734053A (en) | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
HUP9801394A3 (en) | 1995-03-10 | 2000-07-28 | Sanofi Pharmaceuticals Inc New | 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
PL336586A1 (en) * | 1997-04-25 | 2000-07-03 | Pfizer | Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders |
HUP0102543A3 (en) | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
-
1999
- 1999-03-25 HU HU0102543A patent/HUP0102543A3/hu unknown
- 1999-03-25 DE DE69910368T patent/DE69910368T2/de not_active Expired - Fee Related
- 1999-03-25 AT AT03013988T patent/ATE299503T1/de not_active IP Right Cessation
- 1999-03-25 SI SI9930802T patent/SI1371647T1/xx unknown
- 1999-03-25 ES ES03013988T patent/ES2242124T3/es not_active Expired - Lifetime
- 1999-03-25 DK DK99907805T patent/DK1073658T3/da active
- 1999-03-25 IL IL13890799A patent/IL138907A0/xx not_active IP Right Cessation
- 1999-03-25 PL PL99343794A patent/PL343794A1/xx not_active IP Right Cessation
- 1999-03-25 CA CA002329077A patent/CA2329077C/en not_active Expired - Fee Related
- 1999-03-25 TR TR2000/03039T patent/TR200003039T2/xx unknown
- 1999-03-25 CN CNB031579582A patent/CN1229349C/zh not_active Expired - Fee Related
- 1999-03-25 PT PT99907805T patent/PT1073658E/pt unknown
- 1999-03-25 RS YUP-635/00A patent/RS50011B/sr unknown
- 1999-03-25 EP EP99907805A patent/EP1073658B1/en not_active Expired - Lifetime
- 1999-03-25 BR BR9909808-3A patent/BR9909808A/pt not_active Application Discontinuation
- 1999-03-25 EP EP03013988A patent/EP1371647B1/en not_active Expired - Lifetime
- 1999-03-25 ES ES99907805T patent/ES2203078T3/es not_active Expired - Lifetime
- 1999-03-25 WO PCT/IB1999/000519 patent/WO1999054333A1/en active IP Right Grant
- 1999-03-25 SI SI9930361T patent/SI1073658T1/xx unknown
- 1999-03-25 KR KR10-2000-7011569A patent/KR100449790B1/ko not_active IP Right Cessation
- 1999-03-25 PT PT03013988T patent/PT1371647E/pt unknown
- 1999-03-25 EA EA200000969A patent/EA200000969A1/ru unknown
- 1999-03-25 AU AU27425/99A patent/AU748352B2/en not_active Ceased
- 1999-03-25 CN CNB998072885A patent/CN1134442C/zh not_active Expired - Fee Related
- 1999-03-25 ID IDW20002117A patent/ID27036A/id unknown
- 1999-03-25 JP JP2000544672A patent/JP3721077B2/ja not_active Expired - Fee Related
- 1999-03-25 DK DK03013988T patent/DK1371647T3/da active
- 1999-03-25 AT AT99907805T patent/ATE247117T1/de not_active IP Right Cessation
- 1999-03-25 US US09/402,242 patent/US6251904B1/en not_active Expired - Fee Related
- 1999-03-25 DE DE69926154T patent/DE69926154T2/de not_active Expired - Fee Related
- 1999-03-25 SK SK1553-2000A patent/SK15532000A3/sk unknown
- 1999-03-26 TW TW088104856A patent/TW593310B/zh not_active IP Right Cessation
- 1999-04-07 PA PA19998470501A patent/PA8470501A1/es unknown
- 1999-04-13 GT GT199900053A patent/GT199900053A/es unknown
- 1999-04-15 AP APAP/P/1999/001514A patent/AP1022A/en active
- 1999-04-16 CO CO99022946A patent/CO5271649A1/es not_active Application Discontinuation
- 1999-04-16 AR ARP990101780A patent/AR015770A1/es active IP Right Grant
- 1999-04-16 PE PE1999000322A patent/PE20000463A1/es not_active Application Discontinuation
- 1999-04-19 TN TNTNSN99073A patent/TNSN99073A1/fr unknown
- 1999-04-19 DZ DZ990073A patent/DZ2773A1/xx active
- 1999-04-19 MA MA25542A patent/MA26622A1/fr unknown
- 1999-04-20 UY UY25484A patent/UY25484A1/es not_active Application Discontinuation
-
2000
- 2000-09-29 IS IS5650A patent/IS5650A/is unknown
- 2000-10-05 IL IL138907A patent/IL138907A/en unknown
- 2000-10-13 OA OA1200000284A patent/OA11502A/en unknown
- 2000-10-19 NO NO20005255A patent/NO20005255L/no not_active Application Discontinuation
- 2000-10-20 HR HR20000712A patent/HRP20000712A2/hr not_active Application Discontinuation
- 2000-11-15 BG BG104949A patent/BG104949A/xx unknown
-
2001
- 2001-04-30 US US09/845,420 patent/US6458951B2/en not_active Expired - Fee Related
- 2001-11-12 HK HK04107545A patent/HK1064670A1/xx not_active IP Right Cessation
-
2003
- 2003-11-20 JP JP2003390698A patent/JP2004099620A/ja not_active Withdrawn
-
2006
- 2006-11-24 AR ARP060105188A patent/AR057934A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20000712A2 (en) | PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
JP4036836B2 (ja) | 性的機能障害治療用の5型サイクリックグアノシン3′,5′−一リン酸ホスホジエステラーゼ(cGMPPDE5)を阻害するピラゾロピリミジノン類中間体の製造方法 | |
DE69925970T2 (de) | Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion | |
US7262192B2 (en) | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | |
US6670366B1 (en) | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | |
EA004982B1 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО [4,3-d]ПИРИМИДИНА | |
KR20020038941A (ko) | 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-d]피리미딘-7-온 | |
MX2011002340A (es) | Pirazolopirimidinas y su uso para el tratamiento de trastornos del snc. | |
CA2585557C (en) | Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors | |
JPH08253484A (ja) | 1H−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体 | |
MXPA00010388A (es) | Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual | |
CZ20003882A3 (cs) | Pyrazolpyrimidinové inhibitory CGMP PDE5 pro léčbu sexuálních dysfunkcí |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040112 Year of fee payment: 6 |
|
OBST | Application withdrawn |